DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. A Toxicological Profile for Iodine, Draft for Public Comment was released in September 2001. This edition supersedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at: vi Background Information The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) for hazardous substances found at Department of Energy (DOE) waste sites. CERCLA directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. ATSDR and DOE entered into a Memorandum of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles for hazardous substances based upon ATSDR=s or DOE=s identification of need. The current ATSDR priority list of hazardous substances at DOE NPL sites was announced in the Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions. Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure. Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section. NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure. The following additional material can be ordered through the ATSDR Information Center: IODINE viii Case …

Toxicological profile for iodine

Macro To Nano Spectroscopy

Trace elemental analysis was carried out in the biological samples of normal, adenoma and carcinoma thyroids using particle induced X-ray emission technique (PIXE). A 2 MeV proton beam was employed to excite the samples. The elements Cl, K, Ca, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, As, Sr, I, Hg and Pb were identified and their concentrations were estimated. The concentrations of the elements Ca, Cu, Zn, As, I and Hg are found to be much lower in carcinoma thyroid than those in the normal thyroid while the concentration of the elements K, Ti, V, Cr, Mn, Fe, Co and Sr in carcinoma thyroid are higher than the concentrations in normal thyroid. The lower and higher values of some of the elements in carcinoma thyroid may be attributed to some pathological factors.

Trace elemental analysis of adenoma and carcinoma thyroid by PIXE method

Normal human intrathyroidal iodine

Determination of normal human intrathyroidal iodine in Caracas population.

Iodine concentration was measured by X-ray fluorescence in 48 normal thyroid glands obtained at autopsy and in 91 surgical thyroid specimens with a variety of abnormalities. The iodine concentration in normal thyroids ranged from 0.02 to 3.12 mg/g of tissue with a mean value of 1.03 ± 0.67 mg/g. The concentrations in pathological specimens were generally lower with the lowest values found in thyroid cancers. Sixteen (76%) of 21 malignant thyroid specimens analysed had undetectable iodine (< 0.02 mg/g) whereas 22 (96%) of 23 benign nodules had measurable iodine concentrations. The detection of iodine in a thyroid nodule by X-ray fluorescence pre-operatively would significantly decrease the probability of malignancy and the need for surgical excision.

P. C. Turner

Papers

The iodine concentration in benign and malignant thyroid nodules measured by X-ray fluorescence